OpenResearchAlpha

Signal Transduction and Targeted Therapy · 18 Nov 2026

Deep single-cell immune- and signaling profiles predict therapy response in chronic myeloid leukemia within hours

Stein-Erik Gullaksenh-index 10, Mathias Brevik, Erin Craig, Monica Hellesøy, Øystein Sefland, Ulla Olsson-Strömberg, Jesper Stentoft, Johan Richter, Tobias Gedde-Dahl, Robert Tibshirani, Sylvia K. Plevritis, Dominik Wolf, Satu Mustjoki, Henrik Hjorth-Hansen, Bjørn Tore Gjertsenh-index 53

0
Citations
no database records one yet
0
Citations in 2026
so far
53
Leading author's h-index
Bjørn Tore Gjertsen, in QAI's scholar index
90
References
works it cites, from open citation data

Citations by database

Each database indexes a different set of journals, preprints and books, so they are shown side by side rather than blended.

  • OpenCitations0
  • Crossref0
  • Europe PMC0

Citations per year

The current year is still counting.

  • 2026 so far0

Abstract

Abstract Chronic myeloid leukemia (CML) is effectively treated with small molecule BCR::ABL1 tyrosine kinase inhibitors (TKIs) but as in all cancers, early identification of suboptimal responders and non-responders is a challenge. Through mass cytometry analysis of peripheral blood leukocytes collected on the first day of TKI treatment, we generated high-dimensional single-cell data from de novo chronic phase CML patients enrolled in two multicenter clinical trials (clinicaltrials.gov: NCT01725204 and NCT01061177). In leukocytes, dasatinib and nilotinib inhibited intracellular signaling within 1 or 3 h after first oral dose, respectively, and each TKI had a unique signaling signature reflecting its kinase specificity profile beyond BCR::ABL1. From these data, an immune and signaling profile was constructed for each patient that predicted the treatment response (BCR::ABL1 IS , %) during the first 12 months of treatment. The predictive features were drug specific: response to dasatinib was dominated by leukemic burden, neutrophil maturity (pSTAT3 Y705) and immune effector activity (pERK ½ in T- and NK cells), whereas response to nilotinib was driven by the intrinsic signaling states of CD34 + CD38 low CD25 + LSC-like cells (cleaved caspase-3, pCRKL Y207 and STAT3 [total and Y705]). These results show that single cell immune and signaling profiles measured within hours of first dose can predict 12-month treatment response, anticipating future optimization of kinase inhibitor treatment within days rather than months.

What the data shows

  • No database records a citation yet, as is usual for a paper this new.
  • Bjørn Tore Gjertsen has the highest h-index among the authors (53).

Graph

This paper in the middle, its authors and their most-cited papers below, the papers it cites to the left and the papers citing it to the right. The timeline lays every paper out by year.

Citing paper shares an authorAuthor without a profileSize shows citations, or h-index for authors

Select a node for its details. Drag to pan, scroll to zoom, drag a node to move it.

Start with

Authors (15)

Each author's standing in QAI's scholar index: the works their ORCID iD is attached to, and for anyone whose ORCID record names a lab OpenResearch follows, their arXiv preprints matched by name and a shared co-author. Names are as printed on the paper.

ProfileMost-cited paper

Cited by 0 papers

Who cites this paper, from open citation data, with Crossref's record of each; the 100 newest when there are more.

0 shown
No citing papers for this filter.

References (90)

What it cites, from open citation data, with Crossref's record of each.

Sign in to see 70 more references

A free account opens the rest of the citing papers and references on every paper’s page.

Deep single-cell immune- and signaling profiles predict therapy response in chronic myeloid leukemia within hours - QAI OpenResearch